745 related articles for article (PubMed ID: 33491135)
1. Impact of donor and recipient Epstein-Barr Virus serostatus on outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis.
Kołodziejczak M; Gil L; de la Camara R; Styczyński J;
Ann Hematol; 2021 Mar; 100(3):763-777. PubMed ID: 33491135
[TBL] [Abstract][Full Text] [Related]
2. Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.
Styczynski J; Tridello G; Gil L; Ljungman P; Mikulska M; Ward KN; Cordonnier C; de la Camara R; Averbuch D; Knelange N; Socié G; Chevallier P; Blaise D; Yakoub-Agha I; Forcade E; Cornelissen J; Maertens J; Petersen E; Nguyen-Quoc S; Veelken H; Schaap N; Passweg J; Michallet M; Fegueux N; Deconinck E; Russell N; Basak G; Bader P; Montoto S; Kröger N; Cesaro S;
Bone Marrow Transplant; 2019 Dec; 54(12):2060-2071. PubMed ID: 31363166
[TBL] [Abstract][Full Text] [Related]
3. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
4. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allogeneic hematopoietic stem cell transplantation for hematological malignancies.
Xuan L; Huang F; Fan Z; Zhou H; Zhang X; Yu G; Zhang Y; Liu C; Sun J; Liu Q
J Hematol Oncol; 2012 Aug; 5():46. PubMed ID: 22856463
[TBL] [Abstract][Full Text] [Related]
5. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.
Styczynski J; Tridello G; Gil L; Ljungman P; Hoek J; Iacobelli S; Ward KN; Cordonnier C; Einsele H; Socie G; Milpied N; Veelken H; Chevallier P; Yakoub-Agha I; Maertens J; Blaise D; Cornelissen J; Michallet M; Daguindau E; Petersen E; Passweg J; Greinix H; Duarte RF; Kröger N; Dreger P; Mohty M; Nagler A; Cesaro S
J Clin Oncol; 2016 Jul; 34(19):2212-20. PubMed ID: 27091716
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma: the prevalence and impacts on outcomes : EBV and CMV reactivation post allo-HCT in NHL.
Ding Y; Ru Y; Song T; Guo L; Zhang X; Zhu J; Li C; Jin Z; Huang H; Tu Y; Xu M; Xu Y; Chen J; Wu D
Ann Hematol; 2021 Nov; 100(11):2773-2785. PubMed ID: 34480615
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
9. Post-transplant ferritin level predicts outcomes after allogeneic hematopoietic stem cell transplant, independent from pre-transplant ferritin level.
Fingrut W; Law A; Lam W; Michelis FV; Viswabandya A; Lipton JH; Kumar R; Mattsson J; Kim DDH
Ann Hematol; 2021 Mar; 100(3):789-798. PubMed ID: 33415423
[TBL] [Abstract][Full Text] [Related]
10. Impact of donor and recipient characteristics on graft-versus-host disease and survival in HLA-matched sibling hematopoietic stem cell transplantation.
Zhang H
Transfus Apher Sci; 2020 Jun; 59(3):102743. PubMed ID: 32139282
[TBL] [Abstract][Full Text] [Related]
11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
[TBL] [Abstract][Full Text] [Related]
12. National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Saillard C; Crocchiolo R; Furst S; El-Cheikh J; Castagna L; Signori A; Oudin C; Faucher C; Lemarie C; Chabannon C; Granata A; Blaise D
Leuk Lymphoma; 2014 May; 55(5):1106-12. PubMed ID: 23822538
[TBL] [Abstract][Full Text] [Related]
13. Post-transplant cyclophosphamide combined with anti-thymocyte globulin for graft-vs-host disease prophylaxis improves survival and lowers non-relapse mortality in older patients undergoing allogeneic hematopoietic cell transplantation.
Pasic I; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Mattsson J; Michelis FV
Ann Hematol; 2020 Jun; 99(6):1377-1387. PubMed ID: 32382774
[TBL] [Abstract][Full Text] [Related]
14. Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients.
Solh MM; Bashey A; Solomon SR; Morris LE; Zhang X; Brown S; Holland HK
Bone Marrow Transplant; 2018 May; 53(5):576-583. PubMed ID: 29335633
[TBL] [Abstract][Full Text] [Related]
15. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
16. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis.
Düver F; Weißbrich B; Eyrich M; Wölfl M; Schlegel PG; Wiegering V
PLoS One; 2020; 15(2):e0228451. PubMed ID: 32017805
[TBL] [Abstract][Full Text] [Related]
17. Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning.
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg Å; Winiarski J; Ringdén O; Maeurer M; Remberger M; Ernberg I
Oncotarget; 2016 May; 7(21):30230-40. PubMed ID: 27102298
[TBL] [Abstract][Full Text] [Related]
18. Low dose Rituximab for pre-emptive treatment of Epstein Barr virus reactivation after allogenic hematopoietic stem cell transplantation.
Delapierre B; Reman O; Dina J; Breuil C; Bellal M; Johnson-Ansah H; Gac AC; Damaj G; Chantepie S
Curr Res Transl Med; 2019 Nov; 67(4):145-148. PubMed ID: 30871955
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
20. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience.
Zhou L; Gao ZY; Lu DP
Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
